KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Royalty Pharma (RPRX) Assets Average (2020 - 2025)

Historic Assets Average for Royalty Pharma (RPRX) over the last 6 years, with Q3 2025 value amounting to $18.8 billion.

  • Royalty Pharma's Assets Average rose 552.25% to $18.8 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $18.8 billion, marking a year-over-year increase of 552.25%. This contributed to the annual value of $17.3 billion for FY2024, which is 424.53% up from last year.
  • Per Royalty Pharma's latest filing, its Assets Average stood at $18.8 billion for Q3 2025, which was up 552.25% from $18.0 billion recorded in Q2 2025.
  • In the past 5 years, Royalty Pharma's Assets Average registered a high of $18.8 billion during Q3 2025, and its lowest value of $16.0 billion during Q1 2021.
  • For the 5-year period, Royalty Pharma's Assets Average averaged around $17.2 billion, with its median value being $17.2 billion (2022).
  • Its Assets Average has fluctuated over the past 5 years, first crashed by 687.89% in 2023, then surged by 1249.35% in 2024.
  • Over the past 5 years, Royalty Pharma's Assets Average (Quarter) stood at $17.6 billion in 2021, then dropped by 2.16% to $17.2 billion in 2022, then dropped by 6.52% to $16.1 billion in 2023, then increased by 12.49% to $18.1 billion in 2024, then grew by 3.88% to $18.8 billion in 2025.
  • Its Assets Average was $18.8 billion in Q3 2025, compared to $18.0 billion in Q2 2025 and $17.9 billion in Q1 2025.